Pharmerica Corporation (NYSE:PMC) – Research analysts at Barrington Research increased their Q4 2018 earnings per share estimates for shares of Pharmerica Corporation in a research report issued on Thursday. Barrington Research analyst M. Petusky now anticipates that the company will post earnings per share of $0.59 for the quarter, up from their prior estimate of $0.57. Barrington Research has a “Underperform” rating on the stock.

Pharmerica Corporation (NYSE:PMC) last issued its quarterly earnings results on Wednesday, August 2nd. The company reported $0.47 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.47. Pharmerica Corporation had a return on equity of 10.94% and a net margin of 1.05%. The business had revenue of $592 million for the quarter, compared to the consensus estimate of $592.96 million. During the same quarter in the previous year, the company posted $0.47 earnings per share. Pharmerica Corporation’s revenue for the quarter was up 13.9% compared to the same quarter last year.

ILLEGAL ACTIVITY WARNING: “Research Analysts Offer Predictions for Pharmerica Corporation’s Q4 2018 Earnings (PMC)” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/08/07/research-analysts-offer-predictions-for-pharmerica-corporations-q4-2018-earnings-pmc.html.

PMC has been the topic of several other research reports. Zacks Investment Research raised Pharmerica Corporation from a “hold” rating to a “buy” rating and set a $28.00 price objective on the stock in a research note on Saturday, June 24th. ValuEngine downgraded Pharmerica Corporation from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. BidaskClub downgraded Pharmerica Corporation from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. Credit Suisse Group downgraded Pharmerica Corporation from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $28.95 to $19.20 in a research note on Friday. They noted that the move was a valuation call. Finally, KeyCorp downgraded Pharmerica Corporation to an “overweight” rating in a research note on Wednesday, August 2nd. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $25.48.

Hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. increased its stake in shares of Pharmerica Corporation by 6.5% in the first quarter. JPMorgan Chase & Co. now owns 270,769 shares of the company’s stock valued at $6,336,000 after buying an additional 16,613 shares during the last quarter. Comerica Bank increased its stake in shares of Pharmerica Corporation by 17.1% in the first quarter. Comerica Bank now owns 38,381 shares of the company’s stock valued at $912,000 after buying an additional 5,608 shares during the last quarter. Norges Bank acquired a new stake in shares of Pharmerica Corporation during the fourth quarter valued at approximately $3,864,000. Los Angeles Capital Management & Equity Research Inc. increased its stake in shares of Pharmerica Corporation by 12.7% in the first quarter. Los Angeles Capital Management & Equity Research Inc. now owns 11,514 shares of the company’s stock valued at $269,000 after buying an additional 1,300 shares during the last quarter. Finally, Citadel Advisors LLC increased its stake in shares of Pharmerica Corporation by 78.9% in the first quarter. Citadel Advisors LLC now owns 338,128 shares of the company’s stock valued at $7,912,000 after buying an additional 149,142 shares during the last quarter. 92.84% of the stock is currently owned by institutional investors and hedge funds.

About Pharmerica Corporation

Earnings History and Estimates for Pharmerica Corporation (NYSE:PMC)

Receive News & Ratings for Pharmerica Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharmerica Corporation and related companies with MarketBeat.com's FREE daily email newsletter.